CASTLE BIOSCIENCES INC (CSTL)
Sector: Health Care
2026 Annual Meeting Analysis
CASTLE BIOSCIENCES INC · Meeting: May 28, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class I Directors
No TSR trigger applies (CSTL's 3-year return of +12.4% beats the peer median of +7.8% by +4.6pp, well below the 35pp threshold for a low-positive TSR company), no overboarding, no attendance issues, and Ms. Goldberg brings directly relevant diagnostics commercialization expertise.
No TSR trigger applies, no overboarding concerns, all attendance requirements met, and Mr. Harrison has deep dermatology and pharmaceutical commercial experience highly relevant to Castle's core business.
No TSR trigger applies, no overboarding issues, attendance is satisfactory, and Ms. Olson has extensive diagnostics and healthcare executive leadership experience that is directly relevant to Castle's business.
All three Class I director nominees pass the TSR trigger check — Castle's 3-year return of +12.4% outperforms the disclosed compensation peer group median of +7.8% by +4.6 percentage points, far below the 35-percentage-point threshold required to trigger a vote against directors for a company with low-positive absolute TSR. No overboarding, attendance, independence, or qualification concerns were identified for any nominee. All three directors bring strong, relevant industry experience in diagnostics and life sciences.
Say on Pay
✓ FORCEO
Derek J. Maetzold
Total Comp
$6,786,771
Prior Support
94%%
The prior year Say-on-Pay vote received approximately 94% support, well above the 70% threshold, indicating strong shareholder endorsement. The CEO's total compensation of $6,786,771 is within a reasonable range for a founder-CEO of a $747 million diagnostics company delivering $344 million in revenue with 4% year-over-year growth. Pay structure is sound: 52% of the CEO's total compensation is performance-based (cash bonus tied to pre-set revenue and strategic milestones plus performance stock awards tied to a 3-year revenue and adjusted EBITDA targets), the company has a robust clawback policy, and the 2025 bonus payout of 138% of target reflected genuine outperformance — revenue of $344.2 million beat the $301.0 million target by a wide margin. The pay-for-performance alignment is reasonable given that Castle's 3-year stock return of +12.4% outperforms its disclosed peer group median of +7.8%.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
8 yrs
Audit Fees
$2,710,753
Non-Audit Fees
$1,780
KPMG's non-audit fees of $1,780 represent less than 0.1% of audit fees of $2,710,753 — far below the 50% threshold that would raise independence concerns. KPMG has audited Castle since 2018 (approximately 8 years), well short of the 25-year tenure threshold. No material financial restatements were identified, and KPMG is a Big 4 firm appropriate for a company of Castle's size and complexity.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 4
Approval of the Company's Non-Employee Director Compensation Policy
This is a board-initiated proposal seeking shareholder ratification of the updated non-employee director pay policy, which modestly increases the annual cash retainer from $50,000 to $55,000, the initial equity grant for new directors from $350,000 to $400,000, and the annual equity grant from $250,000 to $260,000. These adjustments were supported by an independent compensation consultant (AON) benchmarked against the same peer group used for executive pay, and they represent incremental, market-competitive increases rather than excessive enrichment — actual 2025 director total pay ranged from approximately $281,000 to $317,000, which is reasonable for a company of Castle's size. Shareholder approval of a transparent, codified director pay policy is a positive governance practice that promotes accountability.
Overall Assessment
Castle Biosciences' 2026 annual meeting ballot is straightforward with no significant governance concerns — the three director nominees all pass TSR performance screens, KPMG's audit fees are clean with negligible non-audit work, and the Say-on-Pay program is well-structured with 94% prior-year support and genuine pay-for-performance alignment demonstrated by strong 2025 revenue outperformance. The non-standard Proposal 4 seeking shareholder ratification of the director compensation policy is a positive governance step and warrants support.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing